References
1. Northway WH, Jr., Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276(7):357-68.
2. Philip AG. Chronic lung disease of prematurity: a short history. Semin Fetal Neonatal Med. 2009;14(6):333-8.
3. Young T. An essay on the cohesion of fluids. Philosophical Transactions of the Royal Society of London. 1805;95:65-87.
4. Boys C. Soap-bubbles and the forces which mould them. Being a course of three lectures delivered in the theatre of the London Institution on the afternoons of Dec. 30, 1889, Jan. 1 and 3, 1890, before a juvenile audience. In: Knowledge SfPC, editor. London, New York: E. & J. B. Young; 1890. p. 09-50.
5. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child. 1959;97(5, Part 1):517-23.
6. Silverman WA, Fertig JW, Berger AP. The influence of the thermal environment upon the survival of newly born premature infants. Pediatrics. 1958;22(5):876-86.
7. Usher R. Reduction of Mortality from Respiratory Distress Syndrome of Prematurity with Early Administration of Intravenous Glucose and Sodium Bicarbonate. Pediatrics. 1963;32:966-75.
8. Wilson MG, Mikity VG. A new form of respiratory disease in premature infants. AMA J Dis Child. 1960;99:489-99.
9. Hawker JM, Reynolds EO, Taghizadeh A. Pulmonary surface tension and pathological changes in infants dying after respirator treatment for severe hyaline membrane disease. Lancet. 1967;2(7506):75-7.
10. DeLemos R, Wolfsdorf J, Nachman R, Block AJ, Leiby G, Wilkinson HA, et al. Lung injury from oxygen in lambs: the role of artificial ventilation. Anesthesiology. 1969;30(6):609-18.
11. Giammona ST, Kerner D, Bondurant S. Effect of oxygen breathing at atmospheric pressure on pulmonary surfactant. J Appl Physiol. 1965;20(5):855-8.
12. Kaplan HP, Robinson FR, Kapanci Y, Weibel ER. Pathogenesis and reversibility of the pulmonary lesions of oxygen toxicity in monkeys. I. Clinical and light microscopic studies. Lab Invest. 1969;20(1):94-100.
13. Nash G, Blennerhassett JB, Pontoppidan H. Pulmonary lesions associated with oxygen therapy and artifical ventilation. N Engl J Med. 1967;276(7):368-74.
14. Coalson JJ, Winter VT, Siler-Khodr T, Yoder BA. Neonatal chronic lung disease in extremely immature baboons. Am J Respir Crit Care Med. 1999;160(4):1333-46.
15. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50(4):515-25.
16. McCarthy M. US recommendations for antenatal corticosteroids. Lancet. 1994;343(8899):726.
17. Van Marter LJ, Leviton A, Kuban KC, Pagano M, Allred EN. Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia. Pediatrics. 1990;86(3):331-6.
18. Philip AG. Oxygen plus pressure plus time: the etiology of bronchopulmonary dysplasia. Pediatrics. 1975;55(1):44-50.
19. Workshop on bronchopulmonary dysplasia. Sponsored by the Division of Lung Diseases. National Heart, Lung, and Blood Institute, National Institutes of Health. J Pediatr. 1979;95(5 Pt 2):1-9, 815-920.
20. Avery ME, Tooley WH, Keller JB, Hurd SS, Bryan MH, Cotton RB, et al. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics. 1987;79(1):26-30.
21. Morley CJ, Lau R, De Paoli A, Davis PG. Nasal continuous positive airway pressure: does bubbling improve gas exchange? Arch Dis Child Fetal Neonatal Ed. 2005;90(4):F343-4.
22. Morray JP, Fox WW, Kettrick RG, Downes JJ. Clinical correlates of successful weaning from mechanical ventilation in severe bronchopulmonary dysplasia. Crit Care Med. 1981;9(12):815-8.
23. Pinney MA, Cotton EK. Home management of bronchopulmonary dysplasia. Pediatrics. 1976;58(6):856-9.
24. Philip AG, Peabody JL, Lucey JF. Transcutaneous Po2 monitoring in the home management of bronchopulmonary dysplasia. Pediatrics. 1978;61(4):655-7.
25. Saugstad OD. Oxygen radicals and pulmonary damage. Pediatr Pulmonol. 1985;1(3):167-75.
26. Mishra OP, Delivoria-Papadopoulos M. Lipid peroxidation in developing fetal guinea pig brain during normoxia and hypoxia. Brain Res Dev Brain Res. 1989;45(1):129-35.
27. Saldanha RL, Cepeda EE, Poland RL. The effect of vitamin E prophylaxis on the incidence and severity of bronchopulmonary dysplasia. J Pediatr. 1982;101(1):89-93.
28. Shenai JP, Kennedy KA, Chytil F, Stahlman MT. Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr. 1987;111(2):269-77.
29. Fujimura M, Takeuchi T, Kitajima H, Nakayama M. Chorioamnionitis and serum IgM in Wilson-Mikity syndrome. Arch Dis Child. 1989;64(10 Spec No):1379-83.
30. Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics. 1985;75(1):106-11.
31. Cummings JJ, D’Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989;320(23):1505-10.
32. Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983;1(8338):1356-8.
33. Philip AG. Treatment of bronchopulmonary dysplasia with corticosteroids. Clin Res. 1974;22:242 (Abstract).
34. Massaro D, Teich N, Maxwell S, Massaro GD, Whitney P. Postnatal development of alveoli. Regulation and evidence for a critical period in rats. J Clin Invest. 1985;76(4):1297-305.
35. Brown ER, Stark A, Sosenko I, Lawson EE, Avery ME. Bronchopulmonary dysplasia: possible relationship to pulmonary edema. J Pediatr. 1978;92(6):982-4.
36. Engelhardt B, Blalock WA, DonLevy S, Rush M, Hazinski TA. Effect of spironolactone-hydrochlorothiazide on lung function in infants with chronic bronchopulmonary dysplasia. J Pediatr. 1989;114(4 Pt 1):619-24.
37. Kao LC, Warburton D, Sargent CW, Platzker AC, Keens TG. Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia. J Pediatr. 1983;103(4):624-9.
38. Kao LC, Durand DJ, Phillips BL, Nickerson BG. Oral theophylline and diuretics improve pulmonary mechanics in infants with bronchopulmonary dysplasia. J Pediatr. 1987;111(3):439-44.
39. Frank L, Sosenko IR. Undernutrition as a major contributing factor in the pathogenesis of bronchopulmonary dysplasia. Am Rev Respir Dis. 1988;138(3):725-9.
40. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet. 1980;1(8159):55-9.
41. Hudak BB, Allen MC, Hudak ML, Loughlin GM. Home oxygen therapy for chronic lung disease in extremely low-birth-weight infants. Am J Dis Child. 1989;143(3):357-60.
42. High-frequency oscillatory ventilation compared with conventional mechanical ventilation in the treatment of respiratory failure in preterm infants. The HIFI Study Group. N Engl J Med. 1989;320(2):88-93.
43. Sotomayor JL, Godinez RI, Borden S, Wilmott RW. Large-airway collapse due to acquired tracheobronchomalacia in infancy. Am J Dis Child. 1986;140(4):367-71.
44. Cohn RC, Kercsmar C, Dearborn D. Safety and efficacy of flexible endoscopy in children with bronchopulmonary dysplasia. Am J Dis Child. 1988;142(11):1225-8.
45. Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res. 1999;46(6):641-3.
46. Horbar JD, Badger GJ, Carpenter JH, Fanaroff AA, Kilpatrick S, LaCorte M, et al. Trends in mortality and morbidity for very low birth weight infants, 1991-1999. Pediatrics. 2002;110(1 Pt 1):143-51.
47. Abman SH, Kinsella JP. Inhaled nitric oxide therapy of pulmonary hypertension and respiratory failure in premature and term neonates. Adv Pharmacol. 1995;34:457-74.
48. Kotecha S, Allen J. Oxygen therapy for infants with chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2002;87(1):F11-4.
49. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000;105(2):295-310.
50. Group BIUKC, Group BIAC, Group BINZC, Stenson BJ, Tarnow-Mordi WO, Darlow BA, et al. Oxygen saturation and outcomes in preterm infants. N Engl J Med. 2013;368(22):2094-104.
51. American Thoracic S, European Respiratory S. ATS/ERS statement: raised volume forced expirations in infants: guidelines for current practice. Am J Respir Crit Care Med. 2005;172(11):1463-71.
52. Stocks J, Sly PD, Tepper RS, Morgan WJ, editors. Infant Respiratory Function Testing. New York: Wiley-Liss, John Wiley & Sons, Inc.; 1996.
53. Panitch HB, Allen JL, Alpert BE, Schidlow DV. Effects of CPAP on lung mechanics in infants with acquired tracheobronchomalacia. Am J Respir Crit Care Med. 1994;150(5 Pt 1):1341-6.
54. Zinman R. Tracheal stenting improves airway mechanics in infants with tracheobronchomalacia. Pediatr Pulmonol. 1995;19(5):275-81.
55. Panitch HB, Keklikian EN, Motley RA, Wolfson MR, Schidlow DV. Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia. Pediatr Pulmonol. 1990;9(3):170-6.
56. Shaffer TH, Alapati D, Greenspan JS, Wolfson MR. Neonatal non-invasive respiratory support: physiological implications. Pediatr Pulmonol. 2012;47(9):837-47.
57. Make BJ, Hill NS, Goldberg AI, Bach JR, Criner GJ, Dunne PE, et al. Mechanical ventilation beyond the intensive care unit. Report of a consensus conference of the American College of Chest Physicians. Chest. 1998;113(5 Suppl):289S-344S.
58. Panitch HB, Downes JJ, Kennedy JS, Kolb SM, Parra MM, Peacock J, et al. Guidelines for home care of children with chronic respiratory insufficiency. Pediatr Pulmonol. 1996;21(1):52-6.
59. Allen J, Zwerdling R, Ehrenkranz R, Gaultier C, Geggel R, Greenough A, et al. Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med. 2003;168(3):356-96.
60. Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007;120(6):1260-9.
61. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr. 2009;154(3):379-84, 84 e1-2.
62. Schmidt B, Roberts R, Millar D, Kirpalani H. Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology. 2008;93(4):284-7.
63. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112-21.
64. Gower WA, Wert SE, Nogee LM. Inherited surfactant disorders. NeoReviews. 2008;9:e458-e67.
65. Pavlovic J, Papagaroufalis C, Xanthou M, Liu W, Fan R, Thomas NJ, et al. Genetic variants of surfactant proteins A, B, C, and D in bronchopulmonary dysplasia. Dis Markers. 2006;22(5-6):277-91.
66. Abman SH, Mourani PM, Sontag M. Bronchopulmonary dysplasia: a genetic disease. Pediatrics. 2008;122(3):658-9.
67. Bhandari V, Gruen JR. The genomics of bronchopulmonary dysplasia. NeoReviews. 2007;8:e336-e44.
68. Jobe AH. Effects of chorioamnionitis on the fetal lung. Clin Perinatol. 2012;39(3):441-57.
69. Jobe AH. Mechanisms of Lung Injury and Bronchopulmonary Dysplasia. Am J Perinatol. 2016;33(11):1076-8.
70. Kallapur SG, Kramer BW, Jobe AH. Ureaplasma and BPD. Semin Perinatol. 2013;37(2):94-101.
71. Thebaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019;5(1):78.
72. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017;10:CD001145.
73. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017;10:CD001146.
74. Jobe AH. Postnatal corticosteroids for bronchopulmonary dysplasia. Clin Perinatol. 2009;36(1):177-88.
75. Hwang SS, Burris HH, Collins JW, Jr., Kirpalani H, Wright CJ. Moving beyond race and ethnicity to understand the effect of inhaled nitric oxide on bronchopulmonary dysplasia prevention. J Pediatr. 2018;201:298-300.
76. Kadmon G, Schiller O, Dagan T, Bruckheimer E, Birk E, Schonfeld T. Pulmonary hypertension specific treatment in infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 2017;52(1):77-83.
77. Guaman MC, Gien J, Baker CD, Zhang H, Austin ED, Collaco JM. Point Prevalence, Clinical Characteristics, and Treatment Variation for Infants with Severe Bronchopulmonary Dysplasia. Am J Perinatol. 2015;32(10):960-7.
78. Abman SH, Nelin LD. Management of the infant with severe bronchopulmonary dysplasia. In: Bancalari E, editor. The Newborn Lung: Neonatology Questions and Controversies. Philadelphia (PA): Elsevier Saunders; 2012. p. 407-25.
79. Napolitano N, Jalal K, McDonough JM, Monk HM, Zhang H, Jensen E, et al. Identifying and treating intrinsic PEEP in infants with severe bronchopulmonary dysplasia. Pediatr Pulmonol. 2019;54(7):1045-51.
80. Eichenwald C, Dysart K, Zhang H, Fox W. Neonatal Partial Liquid Ventilation for the Treatment and Prevention of Bronchopulmonary Dysplasia. Neoreviews. 2020;21(4):e238-e48.
81. Jobe AH, Steinhorn R. Can We Define Bronchopulmonary Dysplasia? J Pediatr. 2017;188:19-23.
82. Tooley WH. Epidemiology of bronchopulmonary dysplasia. J Pediatr. 1979;95(5 Pt 2):851-8.
83. Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr. 1979;95(5 Pt 2):819-23.
84. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988;82(4):527-32.
85. Abman SH, Collaco JM, Shepherd EG, Keszler M, Cuevas-Guaman M, Welty SE, et al. Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia. J Pediatr. 2017;181:12-28 e1.
86. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. JAMA. 2015;314(10):1039-51.
87. Allen JL. Airway function throughout the lifespan: Pediatric origins of adult respiratory disease. Pediatr Investig. 2019;3(4):236-44.
88. Bui DS, Burgess JA, Lowe AJ, Perret JL, Lodge CJ, Bui M, et al. Childhood Lung Function Predicts Adult Chronic Obstructive Pulmonary Disease and Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome. Am J Respir Crit Care Med. 2017;196(1):39-46.
89. McGrath-Morrow SA, Collaco JM. Bronchopulmonary dysplasia: what are its links to COPD? Ther Adv Respir Dis. 2019;13:1753466619892492.